CN111616970A - A cosmetic containing recombinant human auxin liposome and its preparation method - Google Patents
A cosmetic containing recombinant human auxin liposome and its preparation method Download PDFInfo
- Publication number
- CN111616970A CN111616970A CN202010611580.3A CN202010611580A CN111616970A CN 111616970 A CN111616970 A CN 111616970A CN 202010611580 A CN202010611580 A CN 202010611580A CN 111616970 A CN111616970 A CN 111616970A
- Authority
- CN
- China
- Prior art keywords
- recombinant human
- parts
- liposome
- human auxin
- auxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a cosmetic containing recombinant human auxin liposome and a preparation method thereof, and relates to the technical field of cosmetics. The technical key points are as follows: a cosmetic contains recombinant human growth hormone liposome, and the cosmetic contains the recombinant human growth hormone liposome in a weight ratio of one percent to one thousandth. The cosmetic is a skin lotion and comprises the following components in parts by weight: 0.2-2.7 parts of recombinant human auxin liposome; 5-10 parts of water; 40-50 parts of glycerol; 35-45 parts of mineral oil; 30-40 parts of ethylhexyl palmitate; 25-30 parts of 6-aminonicotinamide; 20-30 parts of polydimethylsiloxane; 20-30 parts of polyglycerol; 15-20 parts of distearate; 5-10 parts of squalane; 1-6 parts of sodium hyaluronate; 1-2 parts of methyl hydroxybenzoate. The recombined human auxin liposome is added into the skin moistening milk, and other auxiliary materials such as moisturizing and the like are matched, so that the skin moistening milk has the advantages of promoting cell repair, enhancing cell activity and endowing the skin with smoothness, tenderness and elasticity.
Description
Technical Field
The invention relates to the technical field of cosmetics, in particular to a cosmetic containing recombinant human auxin liposome.
Background
The recombinant human growth hormone (rhGH) is mainly used for growth disorder caused by insufficient secretion of endogenous growth hormone, Turner's syndrome and chronic renal insufficiency. And also has various pharmacological actions of improving the immunity of the organism, promoting the healing of wounds, promoting the regeneration of visceral cells such as heart, liver, kidney, pancreatic islet and the like. At present, the preparation is produced by various enterprises such as Shenzhenjinkxing, Changchun Jinsai, Anhui Anke and the like in China, and the preparation is freeze-dried powder injection or injection. However, administration of rh-GH as a protein hormone has disadvantages of short half-life and poor stability, and frequent injection administration is required for clinical treatment, and it has been observed that anti-growth hormone antibodies are produced or hypersensitivity reaction occurs in some patients.
In the Chinese patent application with publication No. CN1037455A, a cell restoring and beautifying cream is disclosed, which uses natural active protein, such as human growth hormone, to replace the traditional cream using 4-isopropyl catechol or mercuric amino chloride, hydrocinno, hydrogen ester monomethyl ether, etc. as components, thus solving the problems of skin irritation, poor effect of removing pigmentation, even skin allergy, etc. existing in the traditional cream.
However, recombinant human auxin as a protein hormone has the disadvantages of short half-life and poor stability, and frequent injection administration is required in clinical treatment. The obtained cosmetic has short acting duration and poor stability, so that the using effect of the cosmetic is not ideal.
Therefore, a new solution is needed to solve the above problems.
Disclosure of Invention
In view of the defects of the prior art, the invention aims to provide a cosmetic containing recombinant human auxin liposome, which has the advantages of good oxidation resistance and damaged cell repair.
The second purpose of the invention is to provide a preparation method of the cosmetics containing the recombinant human auxin liposome, which has the advantages of simple operation and suitability for large-scale production.
In order to achieve the first purpose, the invention provides the following technical scheme:
a cosmetic contains recombinant human growth hormone liposome, and the cosmetic contains the recombinant human growth hormone liposome in a weight ratio of one percent to one thousandth.
By adopting the technical scheme, the recombinant human auxin is a gene engineering product produced by utilizing a gene engineering technology, has the same structure and physiological function as natural human auxin extracted from human pituitary, is protein consisting of 191 amino acids, and has the molecular weight of 22000 daltons. Proved by a large amount of research data at home and abroad. The protein has multiple physiological functions of controlling the growth of cells, bones and muscles, effectively activating cell functions and the like. The invention creatively adds the recombinant human auxin into the cosmetics, and the obtained cosmetics have the advantages of good anti-aging and damaged cell repairing.
However, recombinant human auxin as a protein hormone has the disadvantages of short half-life and poor stability, and frequent injection administration is required in clinical treatment. When applied directly to cosmetics, the resulting cosmetics have a short duration of action and some users develop anti-auxin antibodies or develop hypersensitivity reactions.
The liposome as the medicine carrier has the characteristics of prolonging the acting time of the medicine, improving the stability and bioavailability of the medicine and the like, can be used as a particle carrier of various protein hormone medicines, prevents people from neutralizing antibodies in body fluid, improves the stability of the medicine, prolongs the half-life of the medicine and improves the curative effect. The invention can prolong the lasting effective time of the recombinant human auxin and improve the stability of the recombinant human auxin by carrying the recombinant human auxin through liposome encapsulation and then applying the recombinant human auxin into cosmetics.
Further preferably, the recombinant human auxin liposome is prepared by the following preparation steps:
step one, preparing a membrane material: dissolving phospholipid and cholesterol in absolute ethyl alcohol, and dissolving by ultrasonic to prepare a membrane material solution;
step two, preparing a medicine solution: weighing recombinant human auxin raw material medicine, and preparing the recombinant human auxin raw material medicine into 10mg/mL medicinal solution by adopting a phosphate buffer solution;
step three; preparing recombinant human auxin liposome: heating the membrane material solution and the medicinal solution in water bath respectively, mixing and stirring for 4-8min, rotary evaporating to remove ethanol, and filtering with filter membrane to obtain recombinant human auxin liposome.
By adopting the technical scheme, the liposome is prepared by adopting an ethanol injection method, the preparation process is easy to operate, the particle size of the obtained liposome is small, and the method is suitable for industrial production of the liposome; in addition, most of ethanol in the suspension is removed by adopting a reduced pressure rotary evaporation mode in the preparation process, so that the concentration of the liposome in the solution is improved.
More preferably, the mass ratio of the phospholipid to the cholesterol is 2: 1.
By adopting the technical scheme, when the weight ratio of the phospholipid to the cholesterol is 2:1, the obtained recombinant human auxin is high in encapsulation rate, uniform in particle size and good in applicability.
More preferably, the recombinant human auxin titer is 1.5mg/amp,4.0 IU/amp.
More preferably, the cosmetic is a skin lotion.
Further preferably, the skin lotion comprises the following components in parts by weight:
recombinant human auxin liposomes: 0.2 to 2.7 portions of
Water: 5-10 parts;
glycerol: 40-50 parts;
mineral oil: 35-45 parts of;
ethylhexyl palmitate: 30-40 parts;
6-aminonicotinamide: 25-30 parts;
polydimethylsiloxane: 20-30 parts of a solvent;
polyglycerol: 20-30 parts of a solvent;
distearate ester: 15-20 parts of a solvent;
squalane: 5-10 parts;
sodium hyaluronate: 1-6 parts;
methyl hydroxybenzoate: 1-2 parts.
By adopting the technical scheme, the added recombinant human auxin is encapsulated and carried by the liposome, so that the stability of the recombinant human auxin is improved, and good effects of resisting aging and oxidation and repairing damaged cells are fully exerted; in addition, the user has high acceptance of the recombinant human auxin liposome, and antibodies and allergic reactions are not easy to occur.
The skin moistening lotion prepared by the invention adopts the recombinant human auxin liposome as a main active component, and is matched with other various auxiliary materials such as moisturizing agent, skin moistening agent, antioxidant and the like, so that the skin moistening lotion has the advantages of high efficiency, oxidation resistance, aging resistance and cell epidermal cell repair.
More preferably, the skin lotion also comprises 0.1-10 parts by weight of vitamin E.
By adopting the technical scheme, a certain amount of vitamin E which is fat-soluble vitamin is added into the emulsion, the hydrolysate is tocopherol which is one of the main antioxidants, and the vitamin E is added into the emulsion, so that the raw materials of other components can be protected from being oxidized and losing efficacy, and the vitamin E also has the advantages of delaying senescence and effectively reducing wrinkles.
In order to achieve the second purpose, the invention provides the following technical scheme:
a method for preparing a cosmetic containing recombinant human auxin liposome comprises the following steps:
s1, mixing water, glycerol, mineral oil, ethylhexyl palmitate, 6-aminonicotinamide, polydimethylsiloxane, polyglycerol, distearate and squalane in corresponding parts by weight, and heating to 60-75 ℃;
s2, mixing the recombinant human auxin liposome and methylparaben, and heating to 30-40 ℃;
s3, mixing the materials obtained in the steps S1 and S2, cooling to 35-45 ℃, uniformly stirring at the rotation speed of 2500rpm of 2000-10 min for 5-10min, and cooling to 25-30 ℃ to obtain the final product.
By adopting the technical scheme, the skin lotion is obtained by adopting the unique preparation method, the operation is simple, the preparation method is suitable for large-scale industrial production, and the prepared skin lotion has good skin care effects of resisting aging and oxidation, repairing damaged skin and the like, and is mild in performance and free of stimulation.
In summary, compared with the prior art, the invention has the following beneficial effects:
(1) the invention creatively adds the recombinant human auxin into the cosmetics, and the obtained cosmetics have the advantages of good anti-aging and damaged cell repairing; in addition, the invention also carries the recombinant human auxin through liposome encapsulation and delivery, and then the recombinant human auxin is applied to cosmetics, so that the continuous effective time of the recombinant human auxin can be prolonged and the stability of the recombinant human auxin can be improved;
(2) the invention adopts the ethanol injection method to prepare the liposome, the preparation process of the method is easy to operate, the particle size of the obtained liposome is smaller, and the method is suitable for the industrialized production of the liposome; in addition, most of ethanol in the suspension is removed by adopting a reduced pressure rotary evaporation mode in the preparation process, so that the concentration of the liposome in the solution is improved;
(3) the invention also provides a skin moisturizing cream containing the recombinant human auxin liposome, which adopts the recombinant human auxin liposome as a main active component and is matched with other auxiliary materials such as various moisturizing agents, skin moisturizing agents, antioxidants and the like, and has the advantages of high efficiency, oxidation resistance, aging resistance and cell epidermal cell repair.
Drawings
FIG. 1 is a flow chart of the preparation process of the skin lotion containing recombinant human auxin liposome.
Detailed Description
The invention is described in detail below with reference to the figures and examples.
Example 1: referring to fig. 1, the skin lotion containing recombinant human auxin liposome is shown in table 1, and is prepared by the following steps:
s1, mixing water, glycerol, mineral oil, ethylhexyl palmitate, 6-aminonicotinamide, polydimethylsiloxane, polyglycerol, distearate and squalane in corresponding parts by weight according to Table 1, and heating to 60 ℃;
s2, mixing the recombinant human auxin liposome and methylparaben, and heating to 30 ℃;
s3, mixing the materials obtained in the step S1 and the step S2, cooling to 35 ℃, uniformly stirring at 2000rpm for 5min, and cooling to 25 ℃ to obtain the product.
In this example, the recombinant human auxin liposome is prepared by the following steps:
step one, preparing a membrane material: dissolving 100mg of phospholipid and 49mg of cholesterol in 25mL of absolute ethyl alcohol, and dissolving by ultrasonic waves for 20s to prepare a membrane material solution;
step two, preparing a medicine solution: taking a recombinant human auxin bulk drug with the titer of 10mg of 1.5mg/amp and the concentration of 4.0IU/amp, and preparing the recombinant human auxin bulk drug into a 10mg/mL drug solution by adopting a phosphate buffer solution with the pH value of 7.4 and the concentration of 0.02 mol/L;
step three; preparing recombinant human auxin liposome: heating the membrane material solution and the medicinal solution to 45 deg.C in water bath, mixing and stirring for 4min, introducing nitrogen at 28 deg.C to remove oxygen, rotary evaporating to remove ethanol, and filtering with 0.22 μm filter membrane under 1500MPa to obtain recombinant human auxin liposome. The encapsulation efficiency of the recombinant human auxin liposome obtained in the example is 83%, and the average particle size is 210 nm.
Examples 2 to 6: a skin lotion containing recombinant human auxin liposome is different from the skin lotion of example 1 in that the components and the corresponding parts by weight are shown in Table 1.
TABLE 1 Components and parts by weight of examples 1-6
Example 7: a skin lotion containing recombinant human auxin liposomes, which is different from the skin lotion prepared in example 1 in that the skin lotion is prepared by the following steps:
s1, mixing water, glycerol, mineral oil, ethylhexyl palmitate, 6-aminonicotinamide, polydimethylsiloxane, polyglycerol, distearate and squalane in corresponding parts by weight according to Table 1, and heating to 75 ℃;
s2, mixing the recombinant human auxin liposome and methylparaben, and heating to 40 ℃;
s3, mixing the materials obtained in the step S1 and the step S2, cooling to 35 ℃, uniformly stirring at the rotating speed of 2500rpm for 10min, and cooling to 30 ℃ to obtain the product.
Example 8: a skin lotion containing recombinant human auxin liposomes, which is different from that of example 1, is characterized in that 0.1 part by weight of vitamin E is further added in step S2.
Example 9: an emollient cream containing recombinant human auxin liposome is different from the emollient cream of example 1 in that the recombinant human auxin liposome is prepared by the following preparation steps:
step one, preparing a membrane material: dissolving 48mg of phospholipid and 23mg of cholesterol in 15mL of absolute ethyl alcohol, and dissolving by ultrasonic waves for 20s to prepare a membrane material solution;
step two, preparing a medicine solution: taking 4.6mg of recombinant human auxin bulk drug with the titer of 1.5mg/amp and 4.0IU/amp, and preparing the bulk drug into a 8mg/mL drug solution by adopting a phosphate buffer solution with the pH value of 7.4 and the concentration of 0.02 mol/L;
step three; preparing recombinant human auxin liposome: heating the membrane material solution and the medicinal solution to 48 deg.C in water bath, mixing and stirring for 4min, introducing nitrogen at 28 deg.C to remove oxygen, rotary evaporating to remove ethanol, and filtering with 0.22 μm filter membrane under 1500MPa to obtain recombinant human auxin liposome. The encapsulation efficiency of the recombinant human auxin liposome obtained in the embodiment is 79%, and the average particle size is 200 nm.
Example 10: an emollient cream containing recombinant human auxin liposome is different from the emollient cream of example 1 in that the recombinant human auxin liposome is prepared by the following preparation steps:
step one, preparing a membrane material: dissolving 200mg of phospholipid and 98mg of cholesterol in 50mL of absolute ethyl alcohol, and dissolving by ultrasonic waves for 20s to prepare a membrane material solution;
step two, preparing a medicine solution: taking a recombinant human auxin bulk drug with 18mg titer of 1.5mg/amp and 4.0IU/amp, and preparing the recombinant human auxin bulk drug into a 10mg/mL drug solution by adopting a phosphate buffer solution with pH of 7.4 and concentration of 0.02 mol/L;
step three; preparing recombinant human auxin liposome: heating the membrane material solution and the medicinal solution to 45 deg.C in water bath, mixing and stirring for 4min, introducing nitrogen at 28 deg.C to remove oxygen, rotary evaporating to remove ethanol, and filtering with 0.22 μm filter membrane under 2200MPa to obtain recombinant human auxin liposome. The encapsulation efficiency of the recombinant human auxin liposome obtained in the embodiment is 84%, and the average particle size is 230 nm.
Comparative example 1: an emollient cream containing recombinant human auxin liposome is different from the emollient cream of example 1 in that the recombinant human auxin liposome is prepared by the following preparation steps:
step one, preparing a membrane material: dissolving 200mg of phospholipid and 98mg of cholesterol in 50mL of absolute ethyl alcohol, and dissolving by ultrasonic waves for 20s to prepare a membrane material solution;
step two, preparing a medicine solution: taking a recombinant human auxin bulk drug with 18mg titer of 1.5mg/amp and 4.0IU/amp, and preparing the recombinant human auxin bulk drug into a 10mg/mL drug solution by adopting a phosphate buffer solution with pH of 7.4 and concentration of 0.8 mol/L;
step three; preparing recombinant human auxin liposome: heating the membrane material solution and the medicinal solution to 45 deg.C in water bath, mixing and stirring for 4min, introducing nitrogen at 28 deg.C to remove oxygen, rotary evaporating to remove ethanol, and filtering with 0.22 μm filter membrane under 2200MPa to obtain recombinant human auxin liposome. The encapsulation efficiency of the recombinant human auxin liposome obtained in the example is 53%, and the average particle size is 280 nm.
Comparative example 2: an emollient cream containing recombinant human auxin liposome is different from the emollient cream of example 1 in that the recombinant human auxin liposome is prepared by the following preparation steps:
step one, preparing a membrane material: dissolving 200mg of phospholipid and 98mg of cholesterol in 50mL of absolute ethyl alcohol, and dissolving by ultrasonic waves for 20s to prepare a membrane material solution;
step two, preparing a medicine solution: taking 18mg of recombinant human auxin bulk drug with the titer of 1.5mg/amp and 4.0IU/amp, and preparing the recombinant human auxin bulk drug into 10mg/mL of drug solution by adopting deionized water;
step three; preparing recombinant human auxin liposome: heating the membrane material solution and the medicinal solution to 55 deg.C in water bath, mixing and stirring for 4min, introducing nitrogen at 28 deg.C to remove oxygen, rotary evaporating to remove ethanol, and filtering with 0.22 μm filter membrane under 2200MPa to obtain recombinant human auxin liposome. The encapsulation efficiency of the recombinant human auxin liposome obtained in the example is 45%, and the average particle size is 282 nm.
Comparative example 3: an emollient cream containing recombinant human auxin liposome is different from the emollient cream of example 1 in that the recombinant human auxin liposome is prepared by the following preparation steps:
step one, preparing a membrane material: dissolving 200mg of phospholipid and 98mg of cholesterol in 50mL of deionized water, and dissolving by ultrasonic treatment for 30s to prepare membrane material emulsion;
step two, preparing a medicine solution: taking a recombinant human auxin bulk drug with 18mg titer of 1.5mg/amp and 4.0IU/amp, and preparing the recombinant human auxin bulk drug into a 10mg/mL drug solution by adopting a phosphate buffer solution with pH of 7.4 and concentration of 0.8 mol/L;
step three; preparing recombinant human auxin liposome: heating the membrane material emulsion and the medicinal solution to 45 ℃ in water bath respectively, mixing and stirring the two for 4min, introducing nitrogen at 28 ℃ to remove oxygen, performing rotary evaporation to remove ethanol, and filtering with a 0.22-micron filter membrane under 2200MPa to obtain the recombinant human auxin liposome. The encapsulation efficiency of the recombinant human auxin liposome obtained in the example is 23%, and the average particle size is 453 nm.
As can be seen from examples 1, 9 and 10 and comparative examples 1, 2 and 3, the recombinant human auxin liposome prepared by the preparation method has good repeatability, and the obtained recombinant human auxin has high encapsulation efficiency which is over 79 percent and uniform particles.
Comparative example 4: a skin lotion, which is different from example 1 in that recombinant human auxin liposome is not added.
Comparative example 5: a skin lotion, which is different from that of example 1 in that recombinant human auxin is used instead of recombinant human auxin.
Performance testing
Examples 1 to 10 and comparative examples 4 to 5 were used as test subjects, and DPPH radical scavenging ability was measured by DPPH oxidation and hydroxyl radical scavenging ability was measured by salicylic acid, and the test results are shown in table 2.
As can be seen from the test data in Table 2, DPPH radical scavenging ratio IC of examples 1-1050Are all less than 0.08, and the hydroxyl radical clearance rate IC50The content of the recombinant human auxin liposome in the skin care cream is less than 0.25 and far less than that in comparative examples 4-5, and the skin care cream has better anti-aging and anti-oxidation effects by adding the recombinant human auxin liposome.
TABLE 2 Oxidation resistance test results
| Group of | DPPH radical scavenging Rate (IC)50,mg/mL) | Hydroxyl radical scavenging rate (IC)50,mg/mL) |
| Example 1 | 0.07 | 0.21 |
| Example 2 | 0.07 | 0.21 |
| Practice ofExample 3 | 0.08 | 0.22 |
| Example 4 | 0.08 | 0.24 |
| Example 5 | 0.07 | 0.22 |
| Example 6 | 0.08 | 0.23 |
| Example 7 | 0.07 | 0.21 |
| Example 8 | 0.08 | 0.23 |
| Example 9 | 0.07 | 0.21 |
| Example 10 | 0.09 | 0.25 |
| Comparative example 4 | 1.82 | 4.62 |
| Comparative example 5 | 1.16 | 5.01 |
And (3) testing the after-sun repairing effect: 300 volunteers whose faces developed redness and stinging due to the long-term solarization work were selected and divided into 12 groups of 25 persons on average, and 12 groups of volunteers were used each time a day and night before falling asleep during the test period using the products of examples 1 to 10 and comparative examples 4 to 5, and the redness and stinging resolution were tested, and the results are shown in Table 3.
As can be seen from the test data in Table 3, the skin lotion prepared by the invention has the curative effect of repairing after being dried by the sun of more than 84 percent, the comparative examples 4-5 are all lower than 60 percent, and the comparative example 4 without the recombinant human growth hormone liposome has the curative effect of only 12 percent. The skin moistening cream prepared by the invention is proved to have obvious effects of repairing cells and skin.
TABLE 3 post-basking repair Performance test results
The above description is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above embodiments, and all technical solutions belonging to the idea of the present invention belong to the protection scope of the present invention. It should be noted that modifications and embellishments within the scope of the invention may occur to those skilled in the art without departing from the principle of the invention, and are considered to be within the scope of the invention.
Claims (8)
1. A cosmetic containing recombinant human auxin liposome is characterized by comprising the recombinant human auxin liposome in a weight ratio of one percent to one thousandth.
2. The cosmetic comprising recombinant human auxin liposomes of claim 1, wherein the recombinant human auxin liposomes are prepared by the following steps:
step one, preparing a membrane material: dissolving phospholipid and cholesterol in absolute ethyl alcohol, and dissolving by ultrasonic to prepare a membrane material solution;
step two, preparing a medicine solution: weighing recombinant human auxin raw material medicine, and preparing the recombinant human auxin raw material medicine into 10mg/mL medicinal solution by adopting a phosphate buffer solution;
step three; preparing recombinant human auxin liposome: heating the membrane material solution and the medicinal solution in water bath respectively, mixing and stirring for 4-8min, rotary evaporating to remove ethanol, and filtering with filter membrane to obtain recombinant human auxin liposome.
3. The cosmetic comprising recombinant human auxin liposomes of claim 2, wherein the mass ratio of phospholipids to cholesterol is 2: 1.
4. The cosmetic comprising recombinant human auxin liposome of claim 2, wherein the recombinant human auxin titer is 1.5mg/amp,4.0 IU/amp.
5. The cosmetic containing recombinant human auxin liposome of claim 1, wherein the cosmetic is a skin moisturizing cream.
6. The cosmetic containing the recombinant human auxin liposome of claim 5, wherein the skin lotion comprises the following components in parts by weight:
recombinant human auxin liposomes: 0.2 to 2.7 portions of
Water: 5-10 parts;
glycerol: 40-50 parts;
mineral oil: 35-45 parts of;
ethylhexyl palmitate: 30-40 parts;
6-aminonicotinamide: 25-30 parts;
polydimethylsiloxane: 20-30 parts of a solvent;
polyglycerol: 20-30 parts of a solvent;
distearate ester: 15-20 parts of a solvent;
squalane: 5-10 parts;
sodium hyaluronate: 1-6 parts;
methyl hydroxybenzoate: 1-2 parts.
7. The cosmetic containing recombinant human auxin liposomes according to claim 6, wherein the skin care lotion further comprises 0.1 to 10 parts by weight of vitamin E.
8. The method for preparing a cosmetic containing recombinant human auxin liposomes according to any of claims 5 to 7, comprising the steps of:
s1, mixing water, glycerol, mineral oil, ethylhexyl palmitate, 6-aminonicotinamide, polydimethylsiloxane, polyglycerol, distearate and squalane in corresponding parts by weight, and heating to 60-75 ℃;
s2, mixing the recombinant human auxin liposome and methylparaben, and heating to 30-40 ℃;
s3, mixing the materials obtained in the steps S1 and S2, cooling to 35-45 ℃, uniformly stirring at the rotation speed of 2500rpm of 2000-10 min for 5-10min, and cooling to 25-30 ℃ to obtain the final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010611580.3A CN111616970A (en) | 2020-06-29 | 2020-06-29 | A cosmetic containing recombinant human auxin liposome and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010611580.3A CN111616970A (en) | 2020-06-29 | 2020-06-29 | A cosmetic containing recombinant human auxin liposome and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111616970A true CN111616970A (en) | 2020-09-04 |
Family
ID=72255654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010611580.3A Withdrawn CN111616970A (en) | 2020-06-29 | 2020-06-29 | A cosmetic containing recombinant human auxin liposome and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111616970A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001058419A1 (en) * | 2000-02-10 | 2001-08-16 | Rhodia Chimie | Cleansing compositions and use of functionalised polyorganosiloxane as make-up removing agent |
| CN101450033A (en) * | 2007-12-04 | 2009-06-10 | 北京医力健生物科技有限公司 | Cosmetic of sexual senility resistant composition and preparation method thereof |
| CN101711729A (en) * | 2009-12-24 | 2010-05-26 | 江西宇骏生物工程有限公司 | Skin care cosmetic containing liposome recombinant human growth hormone and preparation method thereof |
| CN102512370A (en) * | 2011-12-28 | 2012-06-27 | 广州赛莱拉生物科技有限公司 | HSCGF liposome as well as preparation and application thereof |
-
2020
- 2020-06-29 CN CN202010611580.3A patent/CN111616970A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001058419A1 (en) * | 2000-02-10 | 2001-08-16 | Rhodia Chimie | Cleansing compositions and use of functionalised polyorganosiloxane as make-up removing agent |
| CN101450033A (en) * | 2007-12-04 | 2009-06-10 | 北京医力健生物科技有限公司 | Cosmetic of sexual senility resistant composition and preparation method thereof |
| CN101711729A (en) * | 2009-12-24 | 2010-05-26 | 江西宇骏生物工程有限公司 | Skin care cosmetic containing liposome recombinant human growth hormone and preparation method thereof |
| CN102512370A (en) * | 2011-12-28 | 2012-06-27 | 广州赛莱拉生物科技有限公司 | HSCGF liposome as well as preparation and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 国家药品监督管理局: "化妆品准用防腐剂", 《化妆品安全技术规范》 * |
| 杨明 等: "《药剂学》", 31 August 2018, 中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070224150A1 (en) | Growth factor for hair and skin treatment | |
| US8845600B2 (en) | Skin care compositions and uses thereof | |
| AU2017274069B2 (en) | Skin care formulation | |
| CN112656713A (en) | Cosmetic composition containing hyaluronic acid and/or derivatives thereof, and preparation method and application thereof | |
| CN108379215B (en) | Lyophilized powder composition with skin whitening effect and cosmetic composition containing same | |
| CN104780902A (en) | Composition for external use | |
| CN101489541A (en) | Use of polyamines in the treatment of psoriasis | |
| CN113332162A (en) | protamine-PDRN compound, composition and application in preparation of skin care product | |
| JP2000072642A (en) | Slimming agent | |
| CN114796024A (en) | Bionic sebum composition for skin barrier repair and preparation method and application thereof | |
| CN110833519A (en) | Soothing and moisturizing mask liquid containing industrial hemp leaf extract and preparation method thereof | |
| KR102658915B1 (en) | Multi moisturizing agent for cosmetics, Manufacturing method thereof and cosmetics containing the same | |
| CN110151597A (en) | A kind of polypeptide repair latex and preparation method thereof | |
| CN112773761A (en) | Cosmetic composition, essence and preparation method thereof | |
| CN114983856B (en) | Blue copper peptide solution with penetration promoting system and preparation method and application thereof | |
| CN111616970A (en) | A cosmetic containing recombinant human auxin liposome and its preparation method | |
| CN106074365B (en) | A kind of capsaicine ethosome gel and preparation method thereof | |
| CN114712269A (en) | Anti-aging essential oil composition and preparation method and application thereof | |
| JPH101414A (en) | Skin cosmetic | |
| CN112587431A (en) | Brown sugar scrub cream and preparation method thereof | |
| JPH08217688A (en) | Hyaluronidase inhibitor | |
| CN115105424B (en) | Anti-wrinkle firming activator for skin care and preparation method thereof | |
| CN117298026A (en) | Composition and liposome with skin care effect, and preparation method and application thereof | |
| CN115708789B (en) | Application of skin external composition containing cordycepin in preparation of anti-aging cosmetics | |
| RO137322A2 (en) | Active formulas for topical application with healing and anti-acne action used to improve skin quality in skin conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200904 |